Combination of 5% cysteamine and 4% nicotinamide in melasma: Efficacy, tolerability, and safety.

Autor: Crocco EI; Rua Barata Ribeiro, São Paulo, Brazil., Torloni L; Rua Barata Ribeiro, São Paulo, Brazil., Fernandes PB; Rua Barata Ribeiro, São Paulo, Brazil., de Campos MEBB; Rua Barata Ribeiro, São Paulo, Brazil., Gonzaga M; Rua Barata Ribeiro, São Paulo, Brazil., Silva FC; Rua Barata Ribeiro, São Paulo, Brazil., Nasario JPS; Rua Barata Ribeiro, São Paulo, Brazil., Guerra LO; Rua Barata Ribeiro, São Paulo, Brazil., Csipak AR; Rua Barata Ribeiro, São Paulo, Brazil., Castilho VC; Rua Barata Ribeiro, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 May; Vol. 23 (5), pp. 1703-1712. Date of Electronic Publication: 2024 Feb 07.
DOI: 10.1111/jocd.16183
Abstrakt: Background: Melasma is a chronic dermatosis that impacts the patient's quality of life and can present considerable challenges in terms of effective treatment.
Objective: To evaluate the effectiveness, tolerability, and safety of 5% cysteamine combined with 4% nicotinamide in female subjects with melasma.
Methods: This single-center, single-arm, prospective, open-label study evaluated patients with melasma using a combination cream of 5% cysteamine and 4% nicotinamide in a progressive regimen (60 min in the first month, 120 min in the second month, and 180 min in the third month).
Results: Overall, 35 treated subjects exhibited reduced modified Melasma Area and Severity Index (mMASI) (p < 0.001) and decreased MelasQoL scores (p < 0.001), accompanied by improved brightness, luminosity, homogeneity, and spot intensity (p < 0.001). Photographic and colorimetric analysis revealed smaller spots and improved homogeneity.
Limitations: Adherence to progressive daily treatment could not be evaluated long-term.
Conclusion: A combination cream comprising 5% cysteamine and 4% nicotinamide was effective, tolerable, and safe for treating melasma.
(© 2024 Libbs Farmaceutica Ltda. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje